top of page

Adham Elshamy and Dr. Sherif Mahmoud article published in Journal of Pharmacy and Pharmaceutical Sciences

Writer: Erin Jessup
Erin Jessup
5 days ago
2 min read

The cover for the Journal of Pharmacy and Pharmaceutical Sciences, naming it the official journal of the Canadian Society for Pharmaceutical Sciences. The cover is mostly white and red, with a photo of vials containing a red liquid lined up in a sampling machine.

Congratulations to Adham Elshamy, Dr. Sherif Mahmoud & coauthors for the publication of their recent paper in the Journal of Pharmacy and Pharmaceutical Sciences.


Title: Development and stability evaluation of extemporaneously compounded nimodipine oral suspension


Authors: Adham Elshamy, Hasnaa Osama, Afsaneh Lavasanifar, Forugh Sanaee, Jiangnan Hu, Yifu Chu, Lingyun Chen, Sherif Hanafy Mahmoud


Abstract: Background: Aneurysmal subarachnoid hemorrhage (aSAH) is a devastating neurological emergency often complicated by delayed cerebral ischemia. While nimodipine remains the only approved pharmacological intervention proven to improve clinical outcomes in this population, significant pharmacokinetic variability and administration challenges in dysphagic patients severely compromise its consistent clinical efficacy.

Purpose: To formulate an extemporaneously compounded nimodipine oral suspension and to systematically evaluate its physicochemical stability and feeding tube compatibility.

Methods: A compounded nimodipine suspension was prepared in 1:1 ORA-Plus® and ORA-Sweet® vehicles and stored under refrigerated and room temperature conditions for 28 days. Chemical stability was quantified via high-performance liquid chromatography (HPLC). Physical stability was evaluated by measuring pH, particle size, sedimentation volume, zeta potential, and viscosity. Administration feasibility was tested using standard enteral feeding tubes.

Results: The compounded formulation maintained chemical stability (90%–110% recovery) for 3 weeks refrigerated and 4 weeks at room temperature. Compared to the crude dispersion prepared by crushing tablets in water, the compounded suspension demonstrated a more negative baseline zeta potential (−21.43 ± 1.89 mV vs. −8.42 ± 2.28 mV, p < 0.001) and higher sedimentation volume (0.99 ± 0.01 vs. 0.26 ± 0.04, p < 0.001), confirming enhanced homogeneity and dispersibility. Rheological analysis confirmed a shear-thinning profile ideal for enteral delivery. Furthermore, feeding tube administration yielded >98% drug recovery without occlusion.

Conclusion: The compounded nimodipine suspension in this study provides a feasible alternative for enteral nimodipine administration. Future studies are needed to evaluate the formulation’s bioavailability.




Comments


Join our mailing list for updates on publications and events

Thanks for submitting!

​2-142G KATZ Group Centre for Pharmacy and Health Research

​Edmonton, AB Canada T6G 2E1

780-492-5364

© 2024 by Neuro-CPK lab.

bottom of page